STOCK TITAN
  1. Home
  2. Sec-filings
  3. BDRX
  4. [EFFECT] Biodexa Pharmaceuticals Plc SEC Filing

[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 30, 2026
Accession Number: 0001214659-26-003934
Submission Type: POS AM
CIK: 0001643918
Company Name: Biodexa Pharmaceuticals Plc
File Number: 333-281489

Source: View Original Filing on SEC EDGAR

Biodexa Pharmaceuticals plc

NASDAQ:BDRX

View BDRX Stock Overview →

BDRX Rankings

#7079 Ranked by Market Cap
N/A Ranked by Dividends

BDRX Latest News

Mar 31, 2026
Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients
Mar 27, 2026
Preliminary Results for the Year Ended 31 December 2025
Mar 23, 2026
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
Mar 18, 2026
ADR Ratio Change
Mar 9, 2026
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

BDRX Latest SEC Filings

Mar 31, 2026
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing
Mar 31, 2026
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing
Mar 31, 2026
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing
Mar 27, 2026
[POS AM] Biodexa Pharmaceuticals Plc SEC Filing
Mar 27, 2026
[POS AM] Biodexa Pharmaceuticals Plc SEC Filing

BDRX Stock Data

513.00k
617.09k
Biotechnology
Healthcare
Link
United Kingdom
Cardiff